Spanish skincare specialist Almirall has announced results from a new secondary analysis using data from the Phase III ADvocate and ADhere studies of lebrikizum 2 May 2023
The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with faci 21 April 2023
The protocol for the POSITIVE study, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint, has been published in the Brit 12 April 2023
Dermatology company Botanix Pharmaceuticals has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide. 4 April 2023
A few eyebrows might have been raised late last year at the size of the deal when Japanese drugmaker Takeda acquired a selective allosteric tyrosine kinase 2 (T 20 March 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.